Table 2.

Univariate estimates for allogeneic HCT vs. chemotherapy.

Outcome	Myeloablative allogeneic HCT (CIBMTR)		Pediatric chemotherapy (CALGB 10403)
	N	Probability, % (95% CI)	N	Probability, % (95% CI)	P
Overall survival	217		263		<0.001
100-day		95 (88–99)%		99 (98–100)%	0.090
1-year		72 (65–79)%		91 (87–94)%	<0.001
3-year		53 (46–60)%		77 (71–82)%	<0.001
5-year		47 (40–54)%		66 (60–72)%	<0.001
Relapse	215		256		0.016
100-day		0 (0–2)%		0 (0–2)%	0.909
1-year		11 (7–16)%		10 (7–15)%	0.803
3-year		21 (16–27)%		26 (21–32)%	0.216
5-year		23 (17–29)%		34 (28–40)%	0.011
Non-relapse mortality	215		256		<0.001
100-day		1 (0–3)%		1 (0–2)%	0.536
1-year		17 (12–22)%		4 (2–7)%	<0.001
3-year		24 (19–30)%		6 (3–9)%	<0.001
5-year		29 (23–35)%		8 (5–12)%	<0.001
Disease-free survival	215		256		<0.001
100-day		95 (88–99)%		99 (97–100)%	0.133
1-year		66 (59–73)%		85 (80–89)%	<0.001
3-year		50 (43–57)%		68 (62–73)%	<0.001
5-year		44 (38–51)%		58 (52–65)%	0.004